A single case report from Japan is drawing attention across the hematology community after describing how a drug normally reserved for a bone marrow cancer appears to have rescued a 75-year-old man from years of transfusion-dependent nosebleeds caused by hereditary hemorrhagic telangiectasia, a rare inherited vascular disorder also known as HHT or Osler disease. The report, published in the journal Annals of Hematology by Yusuke Okamoto of Kyoto University and colleagues, documents a striking pattern of improvement and relapse that clinicians say provides unusually persuasive evidence for a drug effect, even though it comes from the experience of one patient rather than a controlled trial.
Hereditary hemorrhagic telangiectasia is an autosomal dominant condition affecting roughly one in five to eight thousand people, in which mutations in genes governing blood vessel development produce clusters of dilated, fragile capillaries called telangiectases. These malformed vessels sit directly beneath the skin and mucosal surfaces, most abundantly in the nasal lining, and rupture with minimal provocation. The result is recurrent epistaxis, or nosebleed, which is the most common manifestation of the disease and, in severe cases, leads to chronic iron deficiency and anemia so profound that patients require regular red blood cell transfusions simply to survive. Beyond the nose, the disorder can seed arteriovenous malformations in the lungs, liver, and brain, making it a multisystem disease that demands lifelong surveillance.
Treatment options for severe epistaxis in HHT have long been frustratingly limited. Local measures such as nasal packing, laser ablation, and septodermoplasty offer temporary relief but rarely alter the underlying vascular pathology. Systemic anti-angiogenic therapies, including bevacizumab and thalidomide, have shown clinical benefit in studies and case series by targeting the abnormal vessel growth itself, yet no oral agent has emerged as a reliably effective and well-tolerated standard of care. It is against this backdrop that the Japanese team’s observation carries weight, because it suggests that a newer member of the thalidomide drug family may succeed where its predecessor failed.
The patient at the center of the report carried a double diagnosis. In addition to HHT, he had smoldering multiple myeloma, an early, typically asymptomatic stage of a plasma cell malignancy marked by an IgG-kappa monoclonal protein in his blood. He initially received thalidomide for the hematological condition, a choice that also raised hopes of easing his nosebleeds, since thalidomide’s anti-angiogenic properties had been reported to help some HHT patients. Those hopes were not realized: the nosebleeds continued unabated, and his transfusion requirements persisted, leaving him dependent on repeated red blood cell infusions despite the therapy.
Facing limited efficacy, his physicians switched treatment to pomalidomide, a second-generation immunomodulatory derivative of thalidomide that is more potent against abnormal blood vessel formation and is approved for relapsed multiple myeloma. The dose was a modest 2 milligrams per day, taken orally. What followed was rapid and clinically dramatic. Within three weeks of starting the drug, the frequency and severity of the epistaxis decreased markedly, and the patient no longer needed red blood cell transfusions. For a man whose life had been organized around recurring hemorrhage and hospital visits for infusions, the change represented a fundamental restoration of ordinary daily function.
The story then took a turn that, paradoxically, strengthened the case for the drug’s efficacy. Pomalidomide had to be temporarily discontinued because the patient developed a worsening pleural effusion, an accumulation of fluid around the lungs. Subsequent evaluation attributed the effusion to heart failure rather than to the medication itself, but the interruption created an unplanned experiment. During the treatment pause, the nosebleeds gradually returned, and the patient slid back into transfusion dependence, losing the gains that the drug had delivered. The relapse pattern mirrored the treatment status with uncomfortable precision.
When pomalidomide was reintroduced, the response was again swift. The epistaxis improved rapidly, transfusion independence was restored, and, notably, the pleural effusion did not recur, supporting the conclusion that the fluid accumulation had been driven by the patient’s cardiac condition rather than by the drug. This on-off-on sequence, in which bleeding worsened when the drug was withdrawn and abated when it was resumed, is what epidemiologists describe as a dechallenge-rechallenge pattern, and it is one of the strongest forms of evidence obtainable from a single-patient observation. The authors state that this clinical course strongly suggests a genuine therapeutic effect of pomalidomide on HHT-associated bleeding rather than a coincidental fluctuation in disease severity.
The mechanistic rationale for the observation is grounded in the biology of both the disease and the drug. HHT arises from disrupted signaling in the transforming growth factor beta family, particularly through the endoglin and activin receptor-like kinase pathways, which leads to excessive vessel formation and structural instability of the microvasculature. Thalidomide and its derivatives suppress angiogenesis through multiple routes, including inhibition of vascular endothelial growth factor signaling and modulation of immune and stromal cells in the bone marrow microenvironment. Pomalidomide, as a more potent analog, appears to exert a stronger anti-angiogenic effect at lower doses, which may explain why it succeeded in this patient where thalidomide had failed. Cerebrovascular and systemic effects of the drug class on endothelial cells remain an active area of laboratory investigation, and the Japanese team’s case adds a compelling clinical data point to that basic science literature.
Caution is essential in interpreting a single case. The patient’s smoldering myeloma introduces a second disease process that could theoretically influence bleeding tendencies or vascular health, and the authors themselves note that thalidomide and pomalidomide were administered as an individualized therapeutic approach for the HHT-associated epistaxis rather than as established standard treatment for the plasma cell disorder. The report was conducted in accordance with the Declaration of Helsinki, and informed consent for publication was obtained from the patient. The authors declare no competing interests and received no external funding for the work, and they acknowledge using language-editing tools in preparing the manuscript. None of these details diminish the observation, but they underscore that pomalidomide cannot yet be considered a proven therapy for HHT without controlled studies.
Nevertheless, the implications for patients are significant. Severe transfusion-dependent epistaxis is one of the most debilitating faces of HHT, and the authors conclude that pomalidomide may represent a promising oral therapeutic option for patients with severe disease, particularly when conventional treatments prove insufficient. If the finding is reproduced in larger cohorts or formal trials, it could reshape the therapeutic algorithm for a condition that has long lacked effective systemic options, offering patients a simple daily pill in place of chronic transfusion. For now, the case stands as a vivid example of how careful observation of an individual patient, even one treated for an unrelated condition, can illuminate an unexpected path forward for an entire rare disease community.
Subject of Research: Treatment of transfusion-dependent epistaxis in hereditary hemorrhagic telangiectasia with pomalidomide
Article Title: Pomalidomide successfully treated transfusion-dependent epistaxis in hereditary hemorrhagic telangiectasia: a case report
Article References: Okamoto, Y., Sakamoto, T., Taya, T., & Komiyama, M. (2026). Pomalidomide successfully treated transfusion-dependent epistaxis in hereditary hemorrhagic telangiectasia: a case report. Annals of Hematology. https://doi.org/10.1007/s00277-026-07313-5
Image Credits: AI Generated
DOI: 10.1007/s00277-026-07313-5
Keywords: hereditary hemorrhagic telangiectasia, HHT, Osler disease, pomalidomide, epistaxis, thalidomide, transfusion dependence, anti-angiogenic therapy, multiple myeloma, hematology, case report, rare disease
News Source: Nathaniel Bowman. (October 13, 2026). Myeloma Drug Pomalidomide Halts Severe Nosebleeds in Inherited Vascular Disease. Scienmag.
